News

Collaboration with Davide Seruggia In biomedicine, collaboration is more than a buzzword—it’s an essential component of advancing our understanding of complex diseases. As technology and scientific knowledge evolve, the scope of research has expanded to include numerous specialized fields, each bringing unique insights and tools. Consequently, biomedicine relies increasingly on interdisciplinary research groups, where scientists […]

How to Combat Fungal Infections in Immunocompromised Patients? (Vienna, 17. 10. 2024) A new study from the St. Anna Children’s Cancer Research Institute (St. Anna CCRI) warns of the hidden dangers of invasive fungal infections in immunocompromised patients. The international research team, led by scientists Chantal Lucini, Klára Obrová, and Thomas Lion, has found that

ESCCA Conference 2024: Advancements in Clinical Cell Analysis Margarita Maurer-Granofszky, researcher of the Dworzak group, was invited to present her research at the ESCCA Conference 2024. In her presentations, she highlighted the importance of detecting minimal/measurable residual disease (MRD) in children with acute myeloid leukemia (AML) and how new technologies like artificial intelligence (AI) can

Student Applies AI in Cancer Detection and supports St. Anna CCRI (Vienna, 21.08.2024) Alessandro Rodias, a student from the Sir Karl Popper School in Vienna has explored the potential of radiomics in cancer detection. Through his innovative project, he has demonstrated how artificial intelligence (AI) can be applied to analyze radiological images for improved cancer diagnosis.

New Insights into Risk Factors for a Subtype of Acute Lymphoblastic Leukemia A team around Sabine Strehl and Dagmar Schinnerl has made significant progress in studying a subtype of B-cell acute lymphoblastic leukemia. The research findings, recently published in the Blood Cancer Journal, shed new light on the specific characteristics and risk factors of this

Resistance is Futile: DOC Fellowship for Cancer Resistance Research Leonie Lehmayer, a dedicated early-career researcher at St. Anna Children’s Cancer Research Institute, has recently been awarded a prestigious DOC Fellowship from the Austrian Academy of Sciences. Her PhD project focuses on studying enhancers and their role in drug resistance and relapse in cancer patients. Many

From Research to Clinic: St. Anna CCRI’s Pharmacogenomics Symposium St. Anna CCRI hosted its first pharmacogenomics symposium, showcasing the intersection of science and clinical practice in precision oncology. Renowned speakers Dr. Mary Relling and Dr. William Evans explored the impact of genetic data on drug prescription and the importance of international guideline development, as well

Shining New Light on the Onset of Childhood Cancer  Cell mutations can occur during human embryonic development, potentially leading to childhood cancer such as neuroblastoma. Polina Kameneva, recently appointed as Principal Investigator at St. Anna Children’s Cancer Research Institute (St. Anna CCRI), is dedicated to investigating these critical phases. She employs mini-organ cultures and genetic

Polina Kameneva wins FWF Start Prize (21.06.2024) Yesterday, Polina Kameneva won the prestigious FWF START Prize for her innovative research project. In her project she aims to understand the protective mechanisms of cells at different stages of development, particularly with regard to neuroblastoma. The FWF START Prize provides researchers with a financial basis for carrying out long-term

Replacing animal testing for Langerhans cell histiocytosis Caroline Hutter’s group at St. Anna CCRI recently received a major grant from the FWF to develop advanced, animal-free therapeutic approaches for the treatment of Langerhans cell histiocytosis (LCH). This rare disease, caused by an excessive accumulation of langerin expressing cells, poses a major challenge, especially for young

Innovative stem cell model provides insight into childhood cancer origins Researchers from the University of Sheffield and St. Anna Children’s Cancer Research Institute have created a model designed to investigate the origins of neuroblastoma, a cancer primarily affecting infants and young children. The findings offer hope for the creation of tailored treatments which treat aggressive neuroblastomas

Eleni Tomazou takes up tenure-track assistant professorship at Medical University Vienna (Vienna, 03.05.24) At the beginning of May, Eleni Tomazou took up a §99.5 assistant professorship in sarcoma biology at the Medical University of Vienna. The scientist has been leading a research group on pediatric sarcomas at St. Anna Children’s Cancer Research Institute (CCRI) with great

Long Night of Research 2024: Working together in Childhood Cancer Research Join us on Friday, May 24th, from 5-11 p.m. and dive into the world of childhood cancer research! (Vienna, 29.04.24) The Long Night of Research 2024 is approaching and cordially invites you to explore the world of childhood cancer research under the motto “Innovation through

FWF’s ESPRIT Program supports Research on β-Catenin in Wilms Tumor  The Austrian Science Fund’s ESPRIT program has awarded funding to Maud Plaschka’s project focused on exploring β-catenin’s role in Wilms tumor, recognizing the need for innovative research in pediatric oncology. This initiative aims to determine the therapeutic potential of β-catenin inhibitors, addressing a significant gap

MSCA Postdoctoral Fellowship enables the building of fusion-driven Sarcoma Models Sarcomas, aggressive tumors that primarily affect children and adolescents, are the focus of a new project at St. Anna CCRI.  Despite advanced medicine, survival rates of patients with Sarcomas are low and treatment methods are outdated. Strengthened by a prestigious Marie Curie Postdoctoral Fellowship, Ornella Urzì is

When Acute Lymphoblastic Leukemia (ALL) Transforms (Vienna, 05.04.2024) Acute lymphoblastic leukemia (ALL) is highly treatable. However, for new treatment methods in personalized medicine, subtypes of this leukemia must be studied more thoroughly. A team of researchers from St. Anna Children’s Cancer Research Institute and the University of Padua has now made another step forward in